Our results indicated that FASN plays an essential role in developing sorafenib resistance in HCC by regulating cancer metabolism; thereby, FASN inhibition may be a possible means to improve the efficacy of sorafenib in HCC treatment. Here, FASN is linked to hepatocellular carcinoma.